Taiwan Cosmetic PIF & TFDA Market Survelliance

More than completing a PIF — we first determine whether the product, evidence and regulatory pathway are really ready for Taiwan FDA.

Many international companies approach us by saying: “We need a Taiwan PIF.”
But PIF is often not the first issue that needs to be addressed.

Before building the dossier, more fundamental questions should be answered:
Is the product legally classified as a cosmetic in Taiwan?
Are its ingredients and concentrations acceptable?
Can the intended product name and claims be employed?
Can the manufacturer’s current CPSR and test reports be employed?
What safety evidence is genuinely missing?

Our work therefore does not begin with: “How do we complete the sixteen PIF sections?”

It begins with:
“Can this product, with its current formula, intended use, claims and supporting evidence, be legally and safely marketed in Taiwan?”

What Makes SCG Different from a Standard PIF Preparation Service?

We assess the product before assembling the dossier.

If the underlying classification, formulation, claims or intended use are problematic, a well-organized PIF will not eliminate the regulatory risk at all.

SCG therefore reviews:
Product Classification + Formula + Ingredients + Product Name + Taiwan Label + Claims + Intended Use+ Specific Regulatory Risks

before proceeding with full PIF preparation.
This is particularly critical for products involving professional use, device-assisted applications, unusual ingredients, strong claims or a potential cosmetic / medical-device / drug boundary.

We perform a Gap Analysis before recommending additional testing.

A PIF may require stability, microbiological, preservative efficacy, efficacy and other safety evidence.

However, we do not believe that every product should automatically be placed into the same fixed testing package.

Our first questions are:
What evidence already exists?
What can reasonably be employed?
What is genuinely missing?

Only when the gap analysis identifies missing evidence, then we can recommend an appropriate testing strategy.

The objective is not to generate the largest number of reports, it is to establish sufficient and defensible evidence for the product.

Existing CPSR and international technical data may have significant value.

Korean, EU, Japanese and other international brands often already possess substantial documentation, including:
CPSR, quantitative formula, COAs, raw-material specifications, stability data, microbiological reports, preservative efficacy data, manufacturing information and efficacy evidence.

SCG does not automatically treat Taiwan market entry as:
“Start everything again.”

Instead, we apply an:
International Dossier → Taiwan Compliance Conversion

approach.

We assess what can be employed, what requires adaptation and what genuinely needs to be supplemented for Taiwan FDA’s requirements.

Standard PIF preparation is not always the difficult part.

The difficult questions are often:

Is the product really a cosmetic in Taiwan?
Does “Professional Use Only” create additional regulatory concerns?
Does use with a specific device affect product classification?
Do the manufacturer’s local original test reports adequately support the Taiwan PIF’s requirements?
Can an EU CPSR safety conclusion simply be carried over?
How should confidential quantitative formulation data be managed when the manufacturer does not wish to disclose it directly to the Taiwan distributor?
Have translated marketing claims exceeded what Taiwan permits for cosmetics?

These are not template questions.

They require:Regulatory judgment.

This is where SCG is designed to add value.

Our Three-Stage Approach

Stage 1 — Identify the Risks and Gaps

Before full PIF preparation, SCG assesses:
product classification, quantitative formulation, ingredient compliance, product name, labeling and claims for Taiwan market, professional-use or device-related risks, PIF documentation gaps, and the usability of existing CPSRs and test data.

At the end of this stage, the company should obtain the results of:
What is acceptable, what can be employed, what is missing, what must be corrected, and where additional information are necessary.

Stage 2 — PIF Preparation and Product Safety Assessment

Once the required information has been met, the project proceeds with PIF preparation and safety assessment signed by a qualified safety assessor (qualified by TFDA).

A safety assessment is not simply a document completeness check.

It considers:
ingredient concentration × amount of use × frequency × application area × target population × exposure × toxicology × packaging × product characteristics

before reaching a safety conclusion.

Stage 3 — TFDA Notification and Post-market Support

Depending on the agreed scope, SCG may also assist with:
TFDA product notification, PIF document maintenance, formula or packaging change assessment, label and claims updates, and support when the competent authority requests the PIF or related technical information, as well as the inspections required by TFDA.

A PIF should be maintained throughout the commercial life of the product.

Multiple SKU Should Consider More Than “Price per SKU”

For portfolios involving 20, 60 or 100 products, we do not automatically treat every SKU as a completely independent project.

SCG first evaluates common elements such as:
manufacturers, raw materials, manufacturing process, formula families, packaging similarity, toxicological evidence and existing tests.

We can then establish:
Master Documentation + SKU Gap Matrix

to separate reusable common evidence from items requiring individual product assessment. Of course, this benefit only comes for the company who deliver all documents all together not separately for different times.

The benefit is not simply efficiency.

It also creates a more consistent regulatory and document-management structure across the portfolio.

Why Choose SCG?

1. We begin with “Can the product be marketed this way?” — not simply “How do we build the PIF?”

Classification, formulation, claims and intended-use problems should be discovered before the dossier is completed.

2. We identify real evidence gaps before recommending testing.

If existing reliable evidence can be reasonably employed, then it should be used.

Additional work should address an actual regulatory or safety gap.

3. We understand how international dossiers can be converted for Taiwan’s requirements.

Technical evidence developed for Korea, the EU, the US, Japan and other markets should not automatically lose its value merely because the product enters Taiwan.

4. We support cases that go beyond standard PIF preparation.

Professional-use products, device-related products, unusual ingredients, higher-risk claims, classification questions, inconsistent manufacturer documentation and regulatory inspections often require more than document assembly. This is where the values that SCG brings.

5. We treat the PIF as an evidence chain, not a document checklist.

The formula, toxicology, intended use, test results, claims and safety conclusion should tell the same regulatory story.

The real regulatory question is as Taiwan FDA audits/inspects:

“Why do you consider this product safe and compliant?”

A well-built PIF should be able to answer it. If not, then the PIF is useless.

6. We will consider what happens after the dossier is completed.

The value of a PIF becomes particularly critical when the product changes, a safety issue occurs or a competent authority request supporting documentation/physical inspection.

SCG can therefore support ongoing updates, gap remediation and regulatory inspection response.

Before Selecting a Taiwan PIF Service Provider, Ask Yourself These Questions

Will they first confirm whether the product is really a cosmetic in Taiwan?

Will they review formula, label and claims before assembling the PIF?

If a CPSR and international test data already exist, will they evaluate whether those documents can be employed?

If additional testing is recommended, can they explain why it is necessary?

Can they handle professional-use products, device-related use or classification uncertainty?

If the competent authority later requests the PIF, can the provider still support the technical response?

The answers to these questions often reveal more about the real scope of the service than simply comparing the price per SKU.

The SCG Principle

We do not simply complete a PIF for Taiwan FDA. We help determine whether the product, the supporting evidence and the regulatory pathway are genuinely ready for the Taiwan market according to the local regulatory requirements.

Assess first! Employ valid evidence where possible! Fill only the gaps that truly matter!